|

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

RECRUITINGN/ASponsored by Brent Forester
Actively Recruiting
PhaseN/A
SponsorBrent Forester
Started2021-01-28
Est. completion2025-05-31
Eligibility
Age40 Years+
Healthy vol.Accepted
Locations5 sites

Summary

This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.

Eligibility

Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria

1. Diagnosis of Dementia, of the following subtypes,

   1. Alzheimer's dementia, according to NIA-AA Criteria for dementia
   2. Vascular dementia based on:

   i. History consistent with insidious onset of illness and gradual clinical decline ii. MRI evidence of microvascular ischemic disease (microinfarcts) iii. Physical and neurological examination do not indicate current or prior stroke c. Frontotemporal dementia d. Dementia with Lewy Bodies
2. Mini Mental Status Exam (MMSE) less than or equal to 15
3. Cohen-Mansfield Agitation Inventory Nursing Home Version (CMAI) score of 5 or more on at least one item or score of 4 on two items of aggression or physical nonaggression that holds potentially dangerous consequences including hitting (including self), kicking, grabbing onto people, pushing, throwing things, biting, scratching, spitting, hurting self or other, tearing things or destroying property, making physical sexual advances, trying to get to a different place, or intentional falling (items 1-11, 14, 15) OR one score of 5 or more in items of verbal aggression including screaming, making verbal sexual advances, and cursing or verbal aggression (items 22-24).
4. At least one failed pharmacological intervention to manage behavioral symptoms
5. Medically stable for safe administration of ECT verified by standard physical examination, urinalysis and serum chemistries and brain imaging when clinically indicated
6. Comprehension of English language
7. Authorized legal representative able and willing to give informed consent
8. Age 40 and above

Exclusion Criteria:

1. Current diagnosis of co-morbid delirium, measured by the Confusion Assessment Measure (CAM) and by clinical diagnosis
2. Diagnosis of vascular dementia due to stroke, based on:

   * History consistent with abrupt onset and step-wise progression of cognitive and functional decline
   * MRI scan within the past 12 months demonstrating evidence of hemorrhagic and embolic stroke
   * Physical and neurologic examination consistent with current or prior stroke
3. Lifetime or current diagnosis of Schizophrenia, Bipolar Disorder or Schizoaffective Disorder
4. Active substance use disorder within past 6 months
5. Treatment with ECT or other neurostimulation therapies (e.g., TMS or vagal nerve stimulation) within the past 3 months

Conditions3

Agitation,PsychomotorAlzheimer DementiaAlzheimer's Disease

Locations5 sites

Georgia

1 site
Emory Healthcare
Atlanta, Georgia, 30308

Massachusetts

1 site
McLean Hospital
Belmont, Massachusetts, 02478
Jefferson Mattingly, BAjmattingly@mclean.harvard.edu

Michigan

1 site
Pine Rest Christian Mental Health Services
Grand Rapids, Michigan, 49548

Minnesota

1 site
Mayo Clinic
Rochester, Minnesota, 55905

New York

1 site
Northwell Health
Glen Oaks, New York, 11004

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.